An AI-powered biomarker based on histology alone predicted survival among men with metastatic hormone-sensitive prostate cancer and identified those who benefitted from escalation to triplet therapy.

Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates of patients afflicted with prostate adenocarcinoma, which is by far the ...

Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two full years alongside radiation can meaningfully reduce the chance the ...

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

One in every 8 men in the United States will develop prostate cancer, according to prostate cancer statistics released by the American Cancer Society. In the US, advanced prostate cancer diagnoses ...

SAN FRANCISCO -- Prophylactic whole-pelvic radiation therapy (RT) did not perform as expected for patients with unfavorable intermediate-risk or favorable high-risk prostate cancer, according to ...

New technologies can potentially save lives by helping identify prostate cancer earlier, and transforming the way doctors ...